Seeking Alpha

Avanir Pharmaceuticals (AVNR) won FDA approval for Nuedexta, which treats MS and Lou Gehrig...

Avanir Pharmaceuticals (AVNR) won FDA approval for Nuedexta, which treats MS and Lou Gehrig patients for bouts of uncontrolled laughter or crying, sending shares up more than 100% premarket. Avanir will begin marketing Nuedexta in Q1, and analysts say the drug could hit $275M in annual sales within three years.
Comments (1)
  • spald_fr
    , contributor
    Comments (2733) | Send Message
     
    $275MM in three years? That would have to include off label usage because there are about 1 million people with moderate to severe PBA.
    1 Nov 2010, 08:20 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector